Oda Y, Kamijyo Y, Okumura T, Tokuriki Y, Yamashita J, Handa H, Aoyama I, Hashi K, Mori K
No Shinkei Geka. 1985 Dec;13(12):1305-11.
During a 6.5-year period from March 1978, 136 patients with brain tumors, which were diagnosed as gliomas or metastatic brain tumors during surgical operation, were treated by the application of sustained release anticancer pellets in seven institutes. Histological diagnosis disclosed that the majority of the tumors were malignant gliomas (61 cases), metastatic brain tumors (35 cases), and benign astrocytoma (17 cases). The anticancer agents (250 mg of 5FU, 1.5 mg of MMC, 250 mg of BUdR and 6,000 iu of urokinase) were sealed in a Silastic silicone tube of 6 mm in diameter, 0.25 mm in wall thickness, and 12 mm in length. The daily delivery of the drugs was (2-3)/10,000 of the original volume. This treatment was combined with surgical and irradiation therapy with or without general chemotherapy. The median survival time of patients with malignant gliomas was 545 days (18 months). The 1-year survival rate was 65.63%, and the 3-year survival rate 16.2%. On the other hand, in patients with benign astrocytomas, the median survival time was 1,500 days (4.1 years), 1-year survival rate 83.75%, and 3-year survival rate 42.84%. In those with metastatic brain tumors, the median survival time was 280 days, 1-year survival rate 43.87%, and 3-year survival rate 24.84%. The present findings revealed that the tube-type anticancer pellets cannot inhibit the growth of the brain tumors located 5 cm from the pellets.
从1978年3月起的6.5年期间，7家机构对136例脑肿瘤患者进行了治疗，这些患者在手术中被诊断为胶质瘤或脑转移瘤。组织学诊断显示，大多数肿瘤为恶性胶质瘤（61例）、脑转移瘤（35例）和良性星形细胞瘤（17例）。将抗癌药物（250毫克5-氟尿嘧啶、1.5毫克丝裂霉素、250毫克溴脱氧尿苷和6000国际单位尿激酶）密封在直径6毫米、壁厚0.25毫米、长度12毫米的硅橡胶管中。药物的日释放量为原液的(2 - 3)/10000。该治疗与手术和放疗联合应用，可加或不加全身化疗。恶性胶质瘤患者的中位生存时间为545天（18个月）。1年生存率为65.63%，3年生存率为16.2%。另一方面，良性星形细胞瘤患者的中位生存时间为1500天（4.1年），1年生存率为83.75%，3年生存率为42.84%。脑转移瘤患者的中位生存时间为280天，1年生存率为43.87%，3年生存率为24.84%。目前的研究结果表明，管型抗癌微球不能抑制距离微球5厘米处脑肿瘤的生长。
